Brokerages Set argenex SE (NASDAQ:ARGX) PT at $709.18

argenex SE (NASDAQ:ARGX) has received a consensus recommendation of “Buy” from the twenty-two ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, nineteen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $709.18.

ARGX has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded argenex from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Baird R W upgraded argenex from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 13th. HC Wainwright restated a “buy” rating and set a $720.00 price objective on shares of argenex in a report on Tuesday, June 10th. William Blair restated an “outperform” rating on shares of argenex in a report on Friday, February 28th. Finally, Wells Fargo & Company lifted their price objective on argenex from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARGX. Point72 Europe London LLP acquired a new position in argenex during the 4th quarter worth $5,839,000. Stephens Inc. AR acquired a new position in argenex during the 4th quarter worth $310,000. Ameriprise Financial Inc. boosted its position in argenex by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company’s stock worth $4,313,000 after acquiring an additional 639 shares during the period. Jones Financial Companies Lllp boosted its position in argenex by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in argenex by 13.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,538 shares of the company’s stock worth $946,000 after acquiring an additional 181 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $537.92 on Monday. The company has a market cap of $32.85 billion, a P/E ratio of 33.18, a PEG ratio of 0.98 and a beta of 0.39. argenex has a one year low of $379.39 and a one year high of $678.21. The business’s 50-day simple moving average is $586.57 and its 200 day simple moving average is $610.16.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenex had a return on equity of 16.15% and a net margin of 40.20%. Analysts predict that argenex will post 3.13 earnings per share for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.